Cardinal Health and Industry Competition
The pharmaceutical and generic drug industries are highly competitive and, simultaneously, tremendously risk oriented. Both of these characteristics are significantly present in the current outlook for Cardinal Health. The producer of generic drugs is a Fortune 500 company which, according to Leger (2012), pulls in roughly $103 billion in revenue on an annual basis. However, the company is also the target of fierce competition from fellow pharmaceutical giants such as the McKesson Corporation and Amerisource Bergen and is the target of troubling legal charges that threaten to impact both its reputation and its profitability. As the discussion here will demonstrate, the above-noted competitors have seized a relative competitive advantage over Cardinal Health. The discussion assesses the nature of the challenges thereby imposed upon Cardinal Health.
First and foremost among the challenges facing Cardinal Health is its own internal and legal crisis. At present, the company is facing a destructive indictment spearheaded by the Drug Enforcement Agency (DEA). According to charges against it, "the DEA accused Cardinal Health. . . Of endangering the public by selling excessive amounts of oxycodone to four Florida pharmacies. The charges came in an immediate suspension order served Feb. 3 when the agency suspended Cardinal's license to distribute controlled substances...
Cardinal Health, its mission and its current situation. An environmental analysis is presented to analyze the current environment in which the company operates. A SWOT analysis summarizes the company's internal strengths, weaknesses, potential opportunities, and potential threats. The issue in the case study is overviewed, and supporting facts and significant factors are presented that support the problem. Three potential alternative solutions are given, with an evaluation of each solution's
Health Care The developed worlds are becoming older. America's population is approaching retirement age due in large part to the baby boomer generation. Those individuals born between 1946 and 1964 will be eligible for more social security and retirement benefits as time passes. As such, pharmaceutical companies, health services, and the medical industry at large will benefit from this influx of older individuals. As competition for new patents, facilities, drugs and
McKesson Corporation (Mckesson) is an American pharmaceutical distributor with operations mainly in the U.S. The firm has been in operation since 1833, and boasts extensive market share, robust financial strength, and strong market power. The firm has built strong relationships with its key stakeholders, which adds to its strengths. Nonetheless, limited diversification and market focus as well as the threats of competition, unfavourable regulatory changes, and counterfeits present significant concerns
GLAXOSMITHKLINE (GSK) - SUCCESSFUL INTERNAL INNOVATION Read case study answer 4 questions . Do write a report. 1. Based GSK's past performance, critical implementation issues GSK internal innovation? Justify answer. GlaxoSmithKline (GSK) -- Successful Internal Innovation Critical implementation issues for GSK with regards to internal innovation Implementation processes are complex endeavors which need to be thoroughly assessed and carefully decided upon. This is true in any situation and in the case of virtually
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now